Jacqueline Gerhart
Research Subjects
Research Interests
Jacqueline Gerhart has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Gonzalez
Division of Clinical Pharmacology, Department of Medicine, Duke University School of Medicine, Durham, USA
4 shared publications - Andrea N. Edginton
University of Waterloo
2 shared publications - Fernando Carreno
GSK Upper Providence Pennsylvania USA
2 shared publications Haihong Shi
Pfizer Research and Development Pfizer Inc Groton Connecticut USA
2 shared publications- Jennifer Hammond
Pfizer Research and Development Pfizer Inc Collegeville Pennsylvania USA
2 shared publications - Ravi Shankar Prasad Singh
Pfizer Inc Cambridge Massachusetts USA
2 shared publications
Latest Publications
- Open Access
- 21 April 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (5) , e70552
A Phase 1 Multiple‐Dose, Open‐Label, Pharmacokinetic Study of Nirmatrelvir/Ritonavir in Healthy Lactating Women
In accordance with the Centers for Disease Control and Prevention recommendations, pregnant women and those with a recent pregnancy (i.e., lactating) are considered at high risk of developing severe COVID‐19 and qualify for treatment with nirmatrelvir/ritonavir. However, clinical data are lacking in this population because breastfeeding women were excluded from the nirmatrelvir/ritonavir clinical development program and pivotal Phase 2/3 studies. We report findings from a prospective Phase 1 trial (NCT05441215) designed and conducted in accordance with the US Food and Drug Administration guidance on clinical lactation studies that evaluated the pharmacokinetics and safety of multiple oral doses of nirmatrelvir/ritonavir in healthy lactating women using paired breast milk and maternal plasma data. Eight participants were enrolled and completed the study. After administration of nirmatrelvir/ritonavir 300 mg/100 mg to steady‐state, the concentrations of both nirmatrelvir and ritonavir in breast milk were consistently lower than maternal plasma. Based on standard infant breast milk consumption (150 mL/kg/day), the mean absolute daily doses of nirmatrelvir and ritonavir that an infant would receive were 0.1595 and 0.0057 mg/kg/day, respectively, representing 1.8% and 0.19% of the bodyweight‐normalized maternal dose. All treatment‐emergent adverse events were mild to moderate in severity. No deaths, serious or severe adverse events, dose reductions, interruptions, or discontinuations were reported. In conclusion, nirmatrelvir/ritonavir 300 mg/100 mg was safe and well tolerated in healthy lactating women, with infant exposure considered to be low and well within the acceptability criteria of < 10% of the body weight‐normalized maternal dose.
- 21 April 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (5) , e70552
Open AccessA Phase 1 Multiple‐Dose, Open‐Label, Pharmacokinetic Study of Nirmatrelvir/Ritonavir in Healthy Lactating Women
In accordance with the Centers for Disease Control and Prevention recommendations, pregnant women and those with a recent pregnancy (i.e., lactating) are considered at high risk of developing severe COVID‐19 and qualify for treatment with nirmatrelvir/ritonavir. However, clinical data are lacking in this population because breastfeeding women were excluded from the nirmatrelvir/ritonavir clinical development program and pivotal Phase 2/3 studies. We report findings from a prospective Phase 1 trial (NCT05441215) designed and conducted in accordance with the US Food and Drug Administration guidance on clinical lactation studies that evaluated the pharmacokinetics and safety of multiple oral doses of nirmatrelvir/ritonavir in healthy lactating women using paired breast milk and maternal plasma data. Eight participants were enrolled and completed the study. After administration of nirmatrelvir/ritonavir 300 mg/100 mg to steady‐state, the concentrations of both nirmatrelvir and ritonavir in breast milk were consistently lower than maternal plasma. Based on standard infant breast milk consumption (150 mL/kg/day), the mean absolute daily doses of nirmatrelvir and ritonavir that an infant would receive were 0.1595 and 0.0057 mg/kg/day, respectively, representing 1.8% and 0.19% of the bodyweight‐normalized maternal dose. All treatment‐emergent adverse events were mild to moderate in severity. No deaths, serious or severe adverse events, dose reductions, interruptions, or discontinuations were reported. In conclusion, nirmatrelvir/ritonavir 300 mg/100 mg was safe and well tolerated in healthy lactating women, with infant exposure considered to be low and well within the acceptability criteria of < 10% of the body weight‐normalized maternal dose.
- Open Access
- 13 March 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 119 (6) , 1604-1613
Safety, Pharmacokinetics, and Dose Recommendations for Nirmatrelvir/Ritonavir in Individuals with Mild to Moderate COVID ‐19 and Severe Renal Impairment
Patients with severe renal impairment and COVID‐19 are at high risk for severe disease and death. Nirmatrelvir/ritonavir, an antiviral therapy for COVID‐19, is eliminated by renal excretion and can accumulate in patients with severe renal impairment. The phase 1 Evaluation of Protease Inhibition for COVID‐19 in Patients with Severe Renal Impairment (EPIC‐SRI) study evaluated the safety and pharmacokinetics of nirmatrelvir/ritonavir for this population. Fifteen participants (3 not requiring hemodialysis, 12 requiring intermittent hemodialysis) received oral nirmatrelvir/ritonavir 300/100 mg on Day 1, followed by nirmatrelvir/ritonavir 150/100 mg once daily on Days 2–5. No treatment‐related adverse events were reported. Geometric mean (coefficient of variation) maximum plasma concentration, plasma trough concentration, and area under the concentration–time curve from 0 to 24 hours for daily dosing of nirmatrelvir for participants from the Intermittent Hemodialysis Cohort were 3280 ng/mL (48%), 2188 ng/mL (81%), and 65,700 ng*h/mL (59%), respectively. Geometric mean (coefficient of variation) nirmatrelvir hemodialysis clearance and fraction removed from the body by hemodialysis were 30.5 mL/min (35%) and 6.9% (138%), respectively. Population pharmacokinetic modeling demonstrated that simulated distributions of nirmatrelvir maximum plasma concentration, minimum trough concentration, and area under the concentration–time curve from 0 to 24 hours for daily dosing at the studied regimen were similar to those for virtual subjects with normal to moderate renal function receiving the approved dose of nirmatrelvir/ritonavir. SARS‐CoV‐2 RNA levels were substantially reduced across both cohorts. Findings suggest that the studied regimen is well tolerated, achieves and maintains adequate exposure, and is suitable for patients with COVID‐19 and severe renal impairment. NCT05487040.
- 13 March 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 119 (6) , 1604-1613
Open AccessSafety, Pharmacokinetics, and Dose Recommendations for Nirmatrelvir/Ritonavir in Individuals with Mild to Moderate COVID ‐19 and Severe Renal Impairment
Patients with severe renal impairment and COVID‐19 are at high risk for severe disease and death. Nirmatrelvir/ritonavir, an antiviral therapy for COVID‐19, is eliminated by renal excretion and can accumulate in patients with severe renal impairment. The phase 1 Evaluation of Protease Inhibition for COVID‐19 in Patients with Severe Renal Impairment (EPIC‐SRI) study evaluated the safety and pharmacokinetics of nirmatrelvir/ritonavir for this population. Fifteen participants (3 not requiring hemodialysis, 12 requiring intermittent hemodialysis) received oral nirmatrelvir/ritonavir 300/100 mg on Day 1, followed by nirmatrelvir/ritonavir 150/100 mg once daily on Days 2–5. No treatment‐related adverse events were reported. Geometric mean (coefficient of variation) maximum plasma concentration, plasma trough concentration, and area under the concentration–time curve from 0 to 24 hours for daily dosing of nirmatrelvir for participants from the Intermittent Hemodialysis Cohort were 3280 ng/mL (48%), 2188 ng/mL (81%), and 65,700 ng*h/mL (59%), respectively. Geometric mean (coefficient of variation) nirmatrelvir hemodialysis clearance and fraction removed from the body by hemodialysis were 30.5 mL/min (35%) and 6.9% (138%), respectively. Population pharmacokinetic modeling demonstrated that simulated distributions of nirmatrelvir maximum plasma concentration, minimum trough concentration, and area under the concentration–time curve from 0 to 24 hours for daily dosing at the studied regimen were similar to those for virtual subjects with normal to moderate renal function receiving the approved dose of nirmatrelvir/ritonavir. SARS‐CoV‐2 RNA levels were substantially reduced across both cohorts. Findings suggest that the studied regimen is well tolerated, achieves and maintains adequate exposure, and is suitable for patients with COVID‐19 and severe renal impairment. NCT05487040.
- 8 April 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 117 (6) , 1495-1498
Empowering Early‐Career Scientists: Opportunities Through ASCPT Programs, Networks, and Communities
Early‐career scientists face unique challenges as they progress in their professional journeys, from navigating new environments and shifting career paths to managing competing priorities. This perspective highlights ASCPT’s programs and initiatives that support early‐career scientists in building a strong professional foundation. It also emphasizes the value of volunteering, networking, and leadership within the society, which can promote career development and strengthen connections within the broader scientific community.
- 8 April 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 117 (6) , 1495-1498
Empowering Early‐Career Scientists: Opportunities Through ASCPT Programs, Networks, and Communities
Early‐career scientists face unique challenges as they progress in their professional journeys, from navigating new environments and shifting career paths to managing competing priorities. This perspective highlights ASCPT’s programs and initiatives that support early‐career scientists in building a strong professional foundation. It also emphasizes the value of volunteering, networking, and leadership within the society, which can promote career development and strengthen connections within the broader scientific community.
- Top Cited PapersOpen Access
- 4 January 2024
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 63 (1) , 27-42
A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir
Nirmatrelvir is a potent and selective inhibitor of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease that is used as an oral antiviral coronavirus disease 2019 (COVID-19) treatment. To sustain unbound systemic trough concentrations above the antiviral in vitro 90% effective concentration value (EC90), nirmatrelvir is coadministered with 100 mg of ritonavir, a pharmacokinetic enhancer. Ritonavir inhibits nirmatrelvir’s cytochrome P450 (CYP) 3A4-mediated metabolism which results in renal elimination becoming the primary route of nirmatrelvir elimination when dosed concomitantly. Nirmatrelvir exhibits absorption-limited nonlinear pharmacokinetics. When coadministered with ritonavir in patients with mild-to-moderate COVID-19, nirmatrelvir reaches a maximum concentration of 3.43 µg/mL (11.7× EC90) in approximately 3 h on day 5 of dosing, with a geometric mean day 5 trough concentration of 1.57 µg/mL (5.4× EC90). Drug interactions with nirmatrelvir/ritonavir (PAXLOVIDTM) are primarily attributed to ritonavir-mediated CYP3A4 inhibition, and to a lesser extent CYP2D6 and P-glycoprotein inhibition. Population pharmacokinetics and quantitative systems pharmacology modeling support twice daily dosing of 300 mg/100 mg nirmatrelvir/ritonavir for 5 days, with a reduced 150 mg/100 mg dose for patients with moderate renal impairment. Rapid clinical development of nirmatrelvir/ritonavir in response to the emerging COVID-19 pandemic was enabled by innovations in clinical pharmacology research, including an adaptive phase 1 trial design allowing direct to pivotal phase 3 development, fluorine nuclear magnetic resonance spectroscopy to delineate absorption, distribution, metabolism, and excretion profiles, and innovative applications of model-informed drug development to accelerate development.
- 4 January 2024
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 63 (1) , 27-42
Top Cited PapersOpen AccessA Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir
Nirmatrelvir is a potent and selective inhibitor of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease that is used as an oral antiviral coronavirus disease 2019 (COVID-19) treatment. To sustain unbound systemic trough concentrations above the antiviral in vitro 90% effective concentration value (EC90), nirmatrelvir is coadministered with 100 mg of ritonavir, a pharmacokinetic enhancer. Ritonavir inhibits nirmatrelvir’s cytochrome P450 (CYP) 3A4-mediated metabolism which results in renal elimination becoming the primary route of nirmatrelvir elimination when dosed concomitantly. Nirmatrelvir exhibits absorption-limited nonlinear pharmacokinetics. When coadministered with ritonavir in patients with mild-to-moderate COVID-19, nirmatrelvir reaches a maximum concentration of 3.43 µg/mL (11.7× EC90) in approximately 3 h on day 5 of dosing, with a geometric mean day 5 trough concentration of 1.57 µg/mL (5.4× EC90). Drug interactions with nirmatrelvir/ritonavir (PAXLOVIDTM) are primarily attributed to ritonavir-mediated CYP3A4 inhibition, and to a lesser extent CYP2D6 and P-glycoprotein inhibition. Population pharmacokinetics and quantitative systems pharmacology modeling support twice daily dosing of 300 mg/100 mg nirmatrelvir/ritonavir for 5 days, with a reduced 150 mg/100 mg dose for patients with moderate renal impairment. Rapid clinical development of nirmatrelvir/ritonavir in response to the emerging COVID-19 pandemic was enabled by innovations in clinical pharmacology research, including an adaptive phase 1 trial design allowing direct to pivotal phase 3 development, fluorine nuclear magnetic resonance spectroscopy to delineate absorption, distribution, metabolism, and excretion profiles, and innovative applications of model-informed drug development to accelerate development.
- Open Access
- 20 July 2023
- Published by Springer Nature in The AAPS Journal
- Vol. 25 (5) , 1-23
Real-World Evidence of the Top 100 Prescribed Drugs in the USA and Their Potential for Drug Interactions with Nirmatrelvir; Ritonavir
Nirmatrelvir (coadministered with ritonavir as PAXLOVIDTM) reduces the risk of COVID-19-related hospitalizations and all-cause death in individuals with mild-to-moderate COVID-19 at high risk of progression to severe disease. Ritonavir is coadministered as a pharmacokinetic enhancer. However, ritonavir may cause drug-drug interactions (DDIs) due to its interactions with various drug-metabolizing enzymes and transporters, including cytochrome P450 (CYP) 3A, CYP2D6, and P-glycoprotein transporters. To better understand the extent of DDIs (or lack thereof) of nirmatrelvir; ritonavir in a clinical setting, this study used real-world evidence (RWE) from the Optum Clinformatics Data Mart database to identify the top 100 drugs most commonly prescribed to US patients at high risk of progression to severe COVID-19 disease. The top 100 drugs were identified based on total counts associated with drugs prescribed to high-risk patients (i.e., ≥ 1 medical condition associated with an increased risk of severe COVID-19) who were continuously enrolled in the database throughout 2019 and had ≥ 1 prescription claim. Each of the 100 drugs was then assessed for DDI risk based on their metabolism, excretion, and transport pathways identified from available US prescribing and medical literature sources. Seventy drugs identified were not expected to have DDIs with nirmatrelvir; ritonavir, including many cardiovascular agents, anti-infectives, antidiabetic agents, and antidepressants. Conversely, 30 drugs, including corticosteroids, narcotic analgesics, anticoagulants, statins, and sedatives/hypnotics, were expected to cause DDIs with nirmatrelvir; ritonavir. This RWE analysis is complementary to the prescribing information and other DDI management tools for guiding healthcare providers in managing DDIs. Graphical Abstract
- 20 July 2023
- Published by Springer Nature in The AAPS Journal
- Vol. 25 (5) , 1-23
Open AccessReal-World Evidence of the Top 100 Prescribed Drugs in the USA and Their Potential for Drug Interactions with Nirmatrelvir; Ritonavir
Nirmatrelvir (coadministered with ritonavir as PAXLOVIDTM) reduces the risk of COVID-19-related hospitalizations and all-cause death in individuals with mild-to-moderate COVID-19 at high risk of progression to severe disease. Ritonavir is coadministered as a pharmacokinetic enhancer. However, ritonavir may cause drug-drug interactions (DDIs) due to its interactions with various drug-metabolizing enzymes and transporters, including cytochrome P450 (CYP) 3A, CYP2D6, and P-glycoprotein transporters. To better understand the extent of DDIs (or lack thereof) of nirmatrelvir; ritonavir in a clinical setting, this study used real-world evidence (RWE) from the Optum Clinformatics Data Mart database to identify the top 100 drugs most commonly prescribed to US patients at high risk of progression to severe COVID-19 disease. The top 100 drugs were identified based on total counts associated with drugs prescribed to high-risk patients (i.e., ≥ 1 medical condition associated with an increased risk of severe COVID-19) who were continuously enrolled in the database throughout 2019 and had ≥ 1 prescription claim. Each of the 100 drugs was then assessed for DDI risk based on their metabolism, excretion, and transport pathways identified from available US prescribing and medical literature sources. Seventy drugs identified were not expected to have DDIs with nirmatrelvir; ritonavir, including many cardiovascular agents, anti-infectives, antidiabetic agents, and antidepressants. Conversely, 30 drugs, including corticosteroids, narcotic analgesics, anticoagulants, statins, and sedatives/hypnotics, were expected to cause DDIs with nirmatrelvir; ritonavir. This RWE analysis is complementary to the prescribing information and other DDI management tools for guiding healthcare providers in managing DDIs. Graphical Abstract
- Open Access
- 8 June 2022
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 43 (7) , 638-649
Leveraging physiologically based pharmacokinetic modeling to optimize dosing for lopinavir/ritonavir with rifampin in pediatric patients
Study Objective: Treatment of HIV and tuberculosis co‐infection leads to significant mortality in pediatric patients, and treatment can be challenging due to the clinically significant drug–drug interaction (DDI) between lopinavir/ritonavir (LPV/RTV) and rifampin. Doubling LPV/RTV results in insufficient lopinavir trough concentrations in pediatric patients. The objective of this study was to leverage physiologically based pharmacokinetic (PBPK) modeling to optimize the adjusted doses of LPV/RTV in children receiving the WHO‐revised doses of rifampin (15 mg/kg daily).Design: Adult and pediatric PBPK models for LPV/RTV with rifampin were developed, including CYP3A and P‐glycoprotein inhibition and induction.Setting (or Data Source): Data for LPV/RTV model development and evaluation were available from the pediatric AIDS Clinical Trials Group.Patients: Dosing simulations were next performed to optimize dosing in children (2 months to 8 years of age).Intervention: Exposure following super‐boosted LPV/RTV with 10 and 15 mg/kg PO daily rifampin was simulated.Measurements and Main Results: Simulated parameters were within twofold observations for LPV, RTV, and rifampin in adults and children ≥2 weeks old. The model predicted that, in healthy adults receiving 400/100 mg oral LPV/RTV twice daily (BID), co‐treatment with 600 mg oral rifampin daily decreased the steady‐state area under the concentration vs. time curve of LPV by 79%, in line with the observed change of 75%. Simulated and observed concentration profiles were comparable for LPV/RTV (230/57.5 mg/m2) PO BID without rifampin and 230/230 mg/m2 LPV/RTV PO BID with 10 mg/kg PO daily rifampin in pediatric patients. Sixteen mg/kg of super‐boosted LPV (LPV/RTV 1:1) PO BID with 15 mg/kg PO daily rifampin achieved simulated LPV troughs >1 mg/L in ≥93% of virtual children weighing 3.0‐24.9 kg, which was comparable with 10 mg/kg PO daily rifampin.Conclusions: Super‐boosted LPV/RTV with 15 mg/kg rifampin achieves therapeutic LPV troughs in HIV/TB‐infected simulated children.
- 8 June 2022
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 43 (7) , 638-649
Open AccessLeveraging physiologically based pharmacokinetic modeling to optimize dosing for lopinavir/ritonavir with rifampin in pediatric patients
Study Objective: Treatment of HIV and tuberculosis co‐infection leads to significant mortality in pediatric patients, and treatment can be challenging due to the clinically significant drug–drug interaction (DDI) between lopinavir/ritonavir (LPV/RTV) and rifampin. Doubling LPV/RTV results in insufficient lopinavir trough concentrations in pediatric patients. The objective of this study was to leverage physiologically based pharmacokinetic (PBPK) modeling to optimize the adjusted doses of LPV/RTV in children receiving the WHO‐revised doses of rifampin (15 mg/kg daily).Design: Adult and pediatric PBPK models for LPV/RTV with rifampin were developed, including CYP3A and P‐glycoprotein inhibition and induction.Setting (or Data Source): Data for LPV/RTV model development and evaluation were available from the pediatric AIDS Clinical Trials Group.Patients: Dosing simulations were next performed to optimize dosing in children (2 months to 8 years of age).Intervention: Exposure following super‐boosted LPV/RTV with 10 and 15 mg/kg PO daily rifampin was simulated.Measurements and Main Results: Simulated parameters were within twofold observations for LPV, RTV, and rifampin in adults and children ≥2 weeks old. The model predicted that, in healthy adults receiving 400/100 mg oral LPV/RTV twice daily (BID), co‐treatment with 600 mg oral rifampin daily decreased the steady‐state area under the concentration vs. time curve of LPV by 79%, in line with the observed change of 75%. Simulated and observed concentration profiles were comparable for LPV/RTV (230/57.5 mg/m2) PO BID without rifampin and 230/230 mg/m2 LPV/RTV PO BID with 10 mg/kg PO daily rifampin in pediatric patients. Sixteen mg/kg of super‐boosted LPV (LPV/RTV 1:1) PO BID with 15 mg/kg PO daily rifampin achieved simulated LPV troughs >1 mg/L in ≥93% of virtual children weighing 3.0‐24.9 kg, which was comparable with 10 mg/kg PO daily rifampin.Conclusions: Super‐boosted LPV/RTV with 15 mg/kg rifampin achieves therapeutic LPV troughs in HIV/TB‐infected simulated children.
- Open Access
- 18 May 2022
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 112 (2) , 391-403
Use of Real‐World Data and Physiologically‐Based Pharmacokinetic Modeling to Characterize Enoxaparin Disposition in Children With Obesity
Dosing guidance for children with obesity is often unknown despite the fact that nearly 20% of US children are classified as obese. Enoxaparin, a commonly prescribed low‐molecular‐weight heparin, is dosed based on body weight irrespective of obesity status to achieve maximum concentration within a narrow therapeutic or prophylactic target range. However, whether children with and without obesity experience equivalent enoxaparin exposure remains unclear. To address this clinical question, 2,825 anti–activated factor X (anti‐Xa) surrogate concentrations were collected from the electronic health records of 596 children, including those with obesity. Using linear mixed‐effects regression models, we observed that 4‐hour anti‐Xa concentrations were statistically significantly different in children with and without obesity, even for children with the same absolute dose (P = 0.004). To further mechanistically explore obesity‐associated differences in anti‐Xa concentration, a pediatric physiologically‐based pharmacokinetic (PBPK) model was developed in adults, and then scaled to children with and without obesity. This PBPK model incorporated binding of enoxaparin to antithrombin to form anti‐Xa and elimination via heparinase‐mediated metabolism and glomerular filtration. Following scaling, the PBPK model predicted real‐world pediatric concentrations well, with an average fold error (standard deviation of the fold error) of 0.82 (0.23) and 0.87 (0.26) in children with and without obesity, respectively. PBPK model simulations revealed that children with obesity have at most 20% higher 4‐hour anti‐Xa concentrations under recommended, total body weight–based dosing compared to children without obesity owing to reduced weight‐normalized clearance. Enoxaparin exposure was better matched across age groups and obesity status using fat‐free mass weight‐based dosing.
- 18 May 2022
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 112 (2) , 391-403
Open AccessUse of Real‐World Data and Physiologically‐Based Pharmacokinetic Modeling to Characterize Enoxaparin Disposition in Children With Obesity
Dosing guidance for children with obesity is often unknown despite the fact that nearly 20% of US children are classified as obese. Enoxaparin, a commonly prescribed low‐molecular‐weight heparin, is dosed based on body weight irrespective of obesity status to achieve maximum concentration within a narrow therapeutic or prophylactic target range. However, whether children with and without obesity experience equivalent enoxaparin exposure remains unclear. To address this clinical question, 2,825 anti–activated factor X (anti‐Xa) surrogate concentrations were collected from the electronic health records of 596 children, including those with obesity. Using linear mixed‐effects regression models, we observed that 4‐hour anti‐Xa concentrations were statistically significantly different in children with and without obesity, even for children with the same absolute dose (P = 0.004). To further mechanistically explore obesity‐associated differences in anti‐Xa concentration, a pediatric physiologically‐based pharmacokinetic (PBPK) model was developed in adults, and then scaled to children with and without obesity. This PBPK model incorporated binding of enoxaparin to antithrombin to form anti‐Xa and elimination via heparinase‐mediated metabolism and glomerular filtration. Following scaling, the PBPK model predicted real‐world pediatric concentrations well, with an average fold error (standard deviation of the fold error) of 0.82 (0.23) and 0.87 (0.26) in children with and without obesity, respectively. PBPK model simulations revealed that children with obesity have at most 20% higher 4‐hour anti‐Xa concentrations under recommended, total body weight–based dosing compared to children without obesity owing to reduced weight‐normalized clearance. Enoxaparin exposure was better matched across age groups and obesity status using fat‐free mass weight‐based dosing.
- Open Access
- 2 May 2022
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 11 (6) , 778-791
Use of physiologically‐based pharmacokinetic modeling to inform dosing of the opioid analgesics fentanyl and methadone in children with obesity
Obesity is an increasingly alarming public health threat, with nearly 20% of children classified as obese in the United States today. Children with obesity are commonly prescribed the opioids fentanyl and methadone, and accurate dosing is critical to reducing the risk of serious adverse events associated with overexposure. However, pharmacokinetic studies in children with obesity are challenging to conduct, so there is limited information to guide fentanyl and methadone dosing in these children. To address this clinical knowledge gap, physiologically‐based pharmacokinetic models of fentanyl and methadone were developed in adults and scaled to children with and without obesity to explore the interplay of obesity, age, and pharmacogenomics. These models included key obesity‐induced changes in physiology and pharmacogenomic effects. Model predictions captured observed concentrations in children with obesity well, with an overall average fold error of 0.72 and 1.08 for fentanyl and methadone, respectively. Model simulations support a reduced fentanyl dose (1 vs. 2 μg/kg/h) starting at an earlier age (6 years) in virtual children with obesity, highlighting the importance of considering both age and obesity status when selecting an infusion rate most likely to achieve steady‐state concentrations within the target range. Methadone dosing simulations highlight the importance of considering genotype in addition to obesity status when possible, as cytochrome P450 (CYP)2B6*6/*6 virtual children with obesity required half the dose to match the exposure of wildtype children without obesity. This physiologically‐based pharmacokinetic modeling approach can be applied to explore dosing of other critical drugs in children with obesity.
- 2 May 2022
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 11 (6) , 778-791
Open AccessUse of physiologically‐based pharmacokinetic modeling to inform dosing of the opioid analgesics fentanyl and methadone in children with obesity
Obesity is an increasingly alarming public health threat, with nearly 20% of children classified as obese in the United States today. Children with obesity are commonly prescribed the opioids fentanyl and methadone, and accurate dosing is critical to reducing the risk of serious adverse events associated with overexposure. However, pharmacokinetic studies in children with obesity are challenging to conduct, so there is limited information to guide fentanyl and methadone dosing in these children. To address this clinical knowledge gap, physiologically‐based pharmacokinetic models of fentanyl and methadone were developed in adults and scaled to children with and without obesity to explore the interplay of obesity, age, and pharmacogenomics. These models included key obesity‐induced changes in physiology and pharmacogenomic effects. Model predictions captured observed concentrations in children with obesity well, with an overall average fold error of 0.72 and 1.08 for fentanyl and methadone, respectively. Model simulations support a reduced fentanyl dose (1 vs. 2 μg/kg/h) starting at an earlier age (6 years) in virtual children with obesity, highlighting the importance of considering both age and obesity status when selecting an infusion rate most likely to achieve steady‐state concentrations within the target range. Methadone dosing simulations highlight the importance of considering genotype in addition to obesity status when possible, as cytochrome P450 (CYP)2B6*6/*6 virtual children with obesity required half the dose to match the exposure of wildtype children without obesity. This physiologically‐based pharmacokinetic modeling approach can be applied to explore dosing of other critical drugs in children with obesity.
- 22 June 2021
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 60 (12) , 1591-1604
Physiologically Based Pharmacokinetic Modeling of Meropenem in Preterm and Term Infants
Background Meropenem is a broad-spectrum carbapenem antibiotic approved by the US Food and Drug Administration for use in pediatric patients, including treating complicated intra-abdominal infections in infants < 3 months of age. The impact of maturation in glomerular filtration rate and tubular secretion by renal transporters on meropenem pharmacokinetics, and the effect on meropenem dosing, remains unknown. We applied physiologically based pharmacokinetic (PBPK) modeling to characterize the disposition of meropenem in preterm and term infants. Methods An adult meropenem PBPK model was developed in PK-Sim® (Version 8) and scaled to infants accounting for renal transporter ontogeny and glomerular filtration rate maturation. The PBPK model was evaluated using 645 plasma concentrations from 181 infants (gestational age 23–40 weeks; postnatal age 1–95 days). The PBPK model-based simulations were performed to evaluate meropenem dosing in the product label for infants < 3 months of age treated for complicated intra-abdominal infections. Results Our model predicted plasma concentrations in infants in agreement with the observed data (average fold error of 0.90). The PBPK model-predicted clearance in a virtual infant population was successfully able to capture the post hoc estimated clearance of meropenem in this population, estimated by a previously published model. For 90% of virtual infants, a 4-mg/L target plasma concentration was achieved for > 50% of the dosing interval following product label-recommended dosing. Conclusions Our PBPK model supports the meropenem dosing regimens recommended in the product label for infants <3 months of age.
- 22 June 2021
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 60 (12) , 1591-1604
Physiologically Based Pharmacokinetic Modeling of Meropenem in Preterm and Term Infants
Background Meropenem is a broad-spectrum carbapenem antibiotic approved by the US Food and Drug Administration for use in pediatric patients, including treating complicated intra-abdominal infections in infants < 3 months of age. The impact of maturation in glomerular filtration rate and tubular secretion by renal transporters on meropenem pharmacokinetics, and the effect on meropenem dosing, remains unknown. We applied physiologically based pharmacokinetic (PBPK) modeling to characterize the disposition of meropenem in preterm and term infants. Methods An adult meropenem PBPK model was developed in PK-Sim® (Version 8) and scaled to infants accounting for renal transporter ontogeny and glomerular filtration rate maturation. The PBPK model was evaluated using 645 plasma concentrations from 181 infants (gestational age 23–40 weeks; postnatal age 1–95 days). The PBPK model-based simulations were performed to evaluate meropenem dosing in the product label for infants < 3 months of age treated for complicated intra-abdominal infections. Results Our model predicted plasma concentrations in infants in agreement with the observed data (average fold error of 0.90). The PBPK model-predicted clearance in a virtual infant population was successfully able to capture the post hoc estimated clearance of meropenem in this population, estimated by a previously published model. For 90% of virtual infants, a 4-mg/L target plasma concentration was achieved for > 50% of the dosing interval following product label-recommended dosing. Conclusions Our PBPK model supports the meropenem dosing regimens recommended in the product label for infants <3 months of age.